Inverse association between liver fat content and hepatic glucose uptake in patients with type 2 diabetes mellitus

Metabolism: Clinical and Experimental

Volumn 57, Issue 10, 2008, Pages 1445-1451

  Borra, Ronald ^a   Lautamäki, Riika ^a   Parkkola, Riita ^a   Komu, Markku ^a   Sijens, Paul E ^b   Hällsten, Kirsti ^a   Bergman, Jörgen ^a   Iozzo, Patricia ^a,c   Nuutila, Pirjo ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; FAT; FATTY ACID; FLUORODEOXYGLUCOSE F 18; GLUCOSE; PLACEBO; ROSIGLITAZONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DIAGNOSTIC IMAGING; DOUBLE BLIND PROCEDURE; FAT CONTENT; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; HYPERINSULINEMIA; INSULIN SENSITIVITY; LIPID METABOLISM; LIVER FAT; LIVER METABOLISM; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; STATISTICS, NONPARAMETRIC; THIAZOLIDINEDIONES;

EID: 51649131420     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2008.05.015     Document Type: Article

References (29)

1. Bellentani S., Saccoccio G., Masutti F., Croce L.S., Brandi G., Sasso F., et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132 (2000) 112-117
2. Ruderman N., Chisholm D., Pi-Sunyer X., and Schneider S. The metabolically obese, normal-weight individual revisited. Diabetes 47 (1998) 699-713
3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346 (2002) 1221-1231
4. Silverman J.F., Pories W.J., and Caro J.F. Liver pathology in diabetes mellitus and morbid obesity. Clinical, pathological, and biochemical considerations. Pathol Annu 24 Pt 1 (1989) 275-302
5. Marchesini G., Brizi M., Morselli-Labate A.M., Bianchi G., Bugianesi E., McCullough A.J., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 107 (1999) 450-455
6. Assy N., Kaita K., Mymin D., Levy C., Rosser B., and Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci 45 (2000) 1929-1934
7. Feigelson E.B., Pfaff W.W., Karmen A., and Steinberg D. The role of plasma free fatty acids in development of fatty liver. J Clin Invest 40 (1961) 2171-2179
8. Iozzo P., Geisler F., Oikonen V., Maki M., Takala T., Solin O., et al. Insulin stimulates liver glucose uptake in humans: an 18F-FDG PET Study. J Nucl Med 44 (2003) 682-689
9. Iozzo P., Hallsten K., Oikonen V., Virtanen K.A., Kemppainen J., Solin O., et al. Insulin-mediated hepatic glucose uptake is impaired in type 2 diabetes: evidence for a relationship with glycemic control. J Clin Endocrinol Metab 88 (2003) 2055-2060
10. Iozzo P., Hallsten K., Oikonen V., Virtanen K.A., Parkkola R., Kemppainen J., et al. Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes. Diabetes Care 26 (2003) 2069-2074
11. Iozzo P., Lautamaki R., Geisler F., Virtanen K.A., Oikonen V., Haaparanta M., et al. Non-esterified fatty acids impair insulin-mediated glucose uptake and disposition in the liver. Diabetologia 47 (2004) 1149-1156
12. Lautamaki R., Airaksinen K.E., Seppanen M., Toikka J., Luotolahti M., Ball E., et al. Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, double-blind, placebo-controlled study. Diabetes 54 (2005) 2787-2794
13. Sijens P.E., Smit G.P., Borgdorff M.A., Kappert P., and Oudkerk M. Multiple voxel 1H MR spectroscopy of phosphorylase-b kinase deficient patients (GSD IXa) showing an accumulation of fat in the liver that resolves with aging. J Hepatol 45 (2006) 851-855
14. Abate N., Garg A., Coleman R., Grundy S.M., and Peshock R.M. Prediction of total subcutaneous abdominal, intraperitoneal, and retroperitoneal adipose tissue masses in men by a single axial magnetic resonance imaging slice. Am J Clin Nutr 65 (1997) 403-408
15. Vanhamme L., van den B.A., and Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 129 (1997) 35-43
16. Thomsen C., Becker U., Winkler K., Christoffersen P., Jensen M., and Henriksen O. Quantification of liver fat using magnetic resonance spectroscopy. Magn Reson Imaging 12 (1994) 487-495
17. Szczepaniak L.S., Babcock E.E., Schick F., Dobbins R.L., Garg A., Burns D.K., et al. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol 276 5 Pt 1 (1999) E977-E989
18. Garbow J.R., Lin X., Sakata N., Chen Z., Koh D., and Schonfeld G. In vivo MRS measurement of liver lipid levels in mice. J Lipid Res 45 (2004) 1364-1371
19. DeFronzo R.A., Tobin J.D., and Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237 (1979) E214-E223
20. Hamacher K., Coenen H.H., and Stocklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27 (1986) 235-238
21. Nuutila P., Koivisto V.A., Knuuti J., Ruotsalainen U., Teras M., Haaparanta M., et al. Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo. J Clin Invest 89 (1992) 1767-1774
22. Alenius S., and Ruotsalainen U. Bayesian image reconstruction for emission tomography based on median root prior. Eur J Nucl Med 24 (1997) 258-265
23. Hallsten K., Virtanen K.A., Lonnqvist F., Sipila H., Oksanen A., Viljanen T., et al. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 51 (2002) 3479-3485
24. Iozzo P., Jarvisalo M.J., Kiss J., Borra R., Naum G.A., Viljanen A., et al. Quantification of liver glucose metabolism by positron emission tomography: validation study in pigs. Gastroenterology 132 (2007) 531-542
25. Lautamaki R., Nuutila P., Airaksinen K.E., Leino A., Hiekkanen H., Turiceanu M., et al. The effect of PPARgamma-agonism on LDL subclass profile in patients with type 2 diabetes and coronary artery disease. Rev Diabet Stud 3 (2006) 31-38
26. Fulgencio J.P., Kohl C., Girard J., and Pegorier J.P. Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats. Diabetes 45 (1996) 1556-1562
27. Ciaraldi T.P., Gilmore A., Olefsky J.M., Goldberg M., and Heidenreich K.A. In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 39 (1990) 1056-1062
28. Tiikkainen M., Hakkinen A.M., Korsheninnikova E., Nyman T., Makimattila S., and Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53 (2004) 2169-2176
29. Lautamaki R., Borra R., Iozzo P., Komu M., Lehtimaki T., Salmi M., et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 291 (2006) E282-E290